TESARO, Inc. (NASDAQ:TSRO) – Research analysts at Leerink Swann raised their FY2017 EPS estimates for shares of TESARO in a research note issued to investors on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the biopharmaceutical company will post earnings per share of ($8.61) for the year, up from their prior estimate of ($8.89). Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2017 earnings at ($2.79) EPS, FY2018 earnings at ($7.75) EPS, FY2019 earnings at ($5.22) EPS, FY2020 earnings at ($2.11) EPS and FY2021 earnings at $0.49 EPS.

Several other equities analysts also recently weighed in on TSRO. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Morgan Stanley reiterated an “overweight” rating and set a $183.00 target price on shares of TESARO in a research report on Thursday, August 10th. Robert W. Baird reiterated a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Evercore ISI initiated coverage on TESARO in a research report on Wednesday, August 16th. They set an “in-line” rating and a $121.00 target price on the stock. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TESARO has an average rating of “Buy” and an average price target of $161.72.

TRADEMARK VIOLATION NOTICE: “TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/17/tesaro-inc-to-post-fy2017-earnings-of-8-61-per-share-leerink-swann-forecasts-tsro.html.

TESARO (TSRO) traded down $2.10 during midday trading on Friday, reaching $85.90. The company had a trading volume of 449,793 shares, compared to its average volume of 1,031,102. TESARO has a 1 year low of $84.42 and a 1 year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. During the same period in the prior year, the business posted ($1.72) earnings per share. The firm’s revenue for the quarter was up 740.3% compared to the same quarter last year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in TESARO by 5.7% during the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after purchasing an additional 195,590 shares in the last quarter. Vanguard Group Inc. grew its position in shares of TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after acquiring an additional 62,104 shares in the last quarter. State Street Corp grew its position in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after acquiring an additional 177,057 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of TESARO by 24.9% in the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock worth $115,616,000 after acquiring an additional 178,406 shares in the last quarter. Finally, BB Biotech AG grew its position in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after acquiring an additional 53,408 shares in the last quarter.

In other TESARO news, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at approximately $1,171,300. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total value of $70,211.20. Following the sale, the senior vice president now owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,692 shares of company stock valued at $4,628,976. Insiders own 40.50% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.